Related references
Note: Only part of the references are listed.Rescue of multiple class II CFTR mutations by elexacaftor plus tezacaftor plus ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
Onofrio Laselva et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
Valeria Capurro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation
Gitte Berkers et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment
Tara N. Guhr Lee et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
Guido Veit et al.
JCI INSIGHT (2020)
Structural identification of a hotspot on CFTR for potentiation
Fangyu Liu et al.
SCIENCE (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Short-term consequences of F508de1-CFTR thermal instability on CFTR-dependent transepithelial currents in human airway epithelial cells
Lionel Froux et al.
SCIENTIFIC REPORTS (2019)
Phosphorylation-dependent modulation of CFTR macromolecular signalling complex activity by cigarette smoke condensate in airway epithelia
Andrea Schnur et al.
SCIENTIFIC REPORTS (2019)
Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants
Puay-Wah Phuan et al.
SCIENTIFIC REPORTS (2019)
Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del
Stephanie Chin et al.
MOLECULAR PHARMACOLOGY (2018)
Structure-guided combination therapy to potently improve the function of mutant CFTRs
Guido Veit et al.
NATURE MEDICINE (2018)
Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry
Anna Zolin et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2018)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mutation-specific downregulation of CFTR2 variants by gating potentiators
Radu G. Avramescu et al.
HUMAN MOLECULAR GENETICS (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Jennifer L. Taylor-Cousar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Development of Automated Patch Clamp Technique to Investigate CFTR Chloride Channel Function
Arnaud Billet et al.
FRONTIERS IN PHARMACOLOGY (2017)
Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
Saumel Ahmadi et al.
NPJ GENOMIC MEDICINE (2017)
Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508de1 CFTR mutations
Johanna F. Dekkers et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Abdul Rehman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiators Protect G551D but Not △F508 CFTR from Thermal Instability
Xuehong Liu et al.
BIOCHEMISTRY (2014)
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Guido Veit et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Deborah M. Cholon et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Tsukasa Okiyoneda et al.
NATURE CHEMICAL BIOLOGY (2013)
Novel Amino-Carbonitrile-Pyrazole Identified in a Small Molecule Screen Activates Wild-Type and ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator in the Absence of a cAMP Agonist
Wan Namkung et al.
MOLECULAR PHARMACOLOGY (2013)
Thermally Unstable Gating of the Most Common Cystic Fibrosis Mutant Channel (ΔF508) RESCUE BY SUPPRESSOR MUTATIONS IN NUCLEOTIDE BINDING DOMAIN 1 AND BY CONSTITUTIVE MUTATIONS IN THE CYTOSOLIC LOOPS
Wei Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Probing Conformational Rescue Induced by a Chemical Corrector of F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutant
Wilson Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
Tsukasa Okiyoneda et al.
SCIENCE (2010)
Molecular modeling of the heterodimer of human CFTR's nucleotide-binding domains using a protein-protein docking approach
Sheng-You Huang et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2009)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia
Chunying Li et al.
CELL (2007)
Mechanisms of disease: Cystic fibrosis
SM Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains
O Moran et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
Discovery of glycine hydrazide pore-occluding CFTR inhibitors: Mechanism, structure-activity analysis, and in vivo efficacy
C Muanprasat et al.
JOURNAL OF GENERAL PHYSIOLOGY (2004)
Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion
TH Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Share Paper
